Dan Brennan
Stock Analyst at TD Cowen
(4.17)
# 509
Out of 5,014 analysts
111
Total ratings
55.56%
Success rate
13.67%
Average return
Main Sectors:
Stocks Rated by Dan Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Buy | $63 → $72 | $65.32 | +10.23% | 3 | Sep 25, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $10 → $12 | $9.17 | +30.86% | 7 | Sep 12, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Buy | $13 → $15 | $15.55 | -3.54% | 1 | Aug 6, 2025 | |
| CAI Caris Life Sciences | Initiates: Buy | $32 | $32.95 | -2.88% | 1 | Jul 14, 2025 | |
| WGS GeneDx Holdings | Maintains: Buy | $135 → $110 | $122.69 | -10.34% | 4 | May 1, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $8 → $2.5 | $3.33 | -24.92% | 4 | Mar 21, 2025 | |
| TEM Tempus AI | Reinstates: Buy | $74 | $103.25 | -28.33% | 2 | Feb 5, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $82 → $86 | $59.32 | +44.98% | 6 | Nov 26, 2024 | |
| NTRA Natera | Maintains: Buy | $155 → $175 | $172.09 | +1.69% | 4 | Nov 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Buy | $240 → $250 | $173.47 | +44.12% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $72 → $70 | $34.63 | +102.14% | 1 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $177 | $97.78 | +81.02% | 12 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $91.77 | +56.91% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $363 → $410 | $327.65 | +25.13% | 3 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $315 | $204.96 | +53.69% | 5 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $153 → $160 | $140.81 | +13.63% | 12 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $28 → $30 | $7.63 | +293.18% | 1 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $31 | $13.75 | +125.45% | 3 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $648 → $658 | $536.19 | +22.72% | 12 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $51 | $41.32 | +23.43% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $56 | $7.75 | +622.58% | 1 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $57 → $32 | $12.07 | +165.12% | 4 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $545 → $546 | $174.82 | +212.32% | 4 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.53 | +54.53% | 1 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $13 → $15 | $1.51 | +893.38% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $207 → $232 | $186.48 | +24.41% | 6 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $770 → $880 | $1,328.53 | -33.76% | 3 | Oct 7, 2020 |
Guardant Health
Sep 25, 2025
Maintains: Buy
Price Target: $63 → $72
Current: $65.32
Upside: +10.23%
NeoGenomics
Sep 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $9.17
Upside: +30.86%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $15.55
Upside: -3.54%
Caris Life Sciences
Jul 14, 2025
Initiates: Buy
Price Target: $32
Current: $32.95
Upside: -2.88%
GeneDx Holdings
May 1, 2025
Maintains: Buy
Price Target: $135 → $110
Current: $122.69
Upside: -10.34%
Maravai LifeSciences Holdings
Mar 21, 2025
Maintains: Neutral
Price Target: $8 → $2.5
Current: $3.33
Upside: -24.92%
Tempus AI
Feb 5, 2025
Reinstates: Buy
Price Target: $74
Current: $103.25
Upside: -28.33%
Exact Sciences
Nov 26, 2024
Maintains: Buy
Price Target: $82 → $86
Current: $59.32
Upside: +44.98%
Natera
Nov 13, 2024
Maintains: Buy
Price Target: $155 → $175
Current: $172.09
Upside: +1.69%
Charles River Laboratories International
Nov 7, 2024
Maintains: Buy
Price Target: $240 → $250
Current: $173.47
Upside: +44.12%
Nov 6, 2024
Maintains: Hold
Price Target: $72 → $70
Current: $34.63
Upside: +102.14%
Nov 5, 2024
Maintains: Buy
Price Target: $166 → $177
Current: $97.78
Upside: +81.02%
Nov 5, 2024
Maintains: Buy
Price Target: $141 → $144
Current: $91.77
Upside: +56.91%
Nov 4, 2024
Maintains: Hold
Price Target: $363 → $410
Current: $327.65
Upside: +25.13%
Oct 23, 2024
Maintains: Buy
Price Target: $310 → $315
Current: $204.96
Upside: +53.69%
Aug 22, 2024
Maintains: Buy
Price Target: $153 → $160
Current: $140.81
Upside: +13.63%
Aug 7, 2024
Maintains: Hold
Price Target: $28 → $30
Current: $7.63
Upside: +293.18%
Jul 29, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $13.75
Upside: +125.45%
Jul 25, 2024
Maintains: Buy
Price Target: $648 → $658
Current: $536.19
Upside: +22.72%
Jul 23, 2024
Maintains: Buy
Price Target: $48 → $51
Current: $41.32
Upside: +23.43%
May 13, 2024
Initiates: Buy
Price Target: $56
Current: $7.75
Upside: +622.58%
May 1, 2024
Downgrades: Hold
Price Target: $57 → $32
Current: $12.07
Upside: +165.12%
Dec 8, 2023
Maintains: Outperform
Price Target: $545 → $546
Current: $174.82
Upside: +212.32%
May 31, 2023
Initiates: Outperform
Price Target: $7
Current: $4.53
Upside: +54.53%
Mar 31, 2023
Upgrades: Outperform
Price Target: $13 → $15
Current: $1.51
Upside: +893.38%
Mar 1, 2021
Upgrades: Buy
Price Target: $207 → $232
Current: $186.48
Upside: +24.41%
Oct 7, 2020
Downgrades: Sell
Price Target: $770 → $880
Current: $1,328.53
Upside: -33.76%